Allogene Therapeutics Inc. Common Stock (ALLO)
Stock · NASDAQ · Health Care
$1.31as of 10/16/2026
Price chart
Active signals
ALLO Signal Track Record
How signals performed across all stocks →What ALLO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -10.7% | 28% | September 18, 2026 |
| Bollinger Band Breakout | 26 | -9.3% | 35% | August 10, 2026 |
| Bollinger Band Breakdown | 23 | -3.1% | 35% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -8.9% | 43% | September 3, 2026 |
| Any 20-session window (baseline) | -3.6% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also d…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 150
- Website
- allogene.com/
Fundamentals
- 1-day range
- $1.3$1.4
- Market cap
- $679.95M
- P/E (trailing)
- —
- P/E (forward)
- -2.13
- EPS (trailing)
- $-0.49
- Dividend yield
- —
- Beta
- 0.74
- Avg. volume
- 5.64M
How Allogene Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 13, 2025 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Allogene Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALLOAllogene Therapeutics Inc. Common Stock$1.31▼ 2.24%Market cap $679.95MP/E —$1.04$4.46
- AGMBAgomAb Therapeutics NV American Depositary Shares$8.28▼ 0.60%Market cap $664.85MP/E —$7.97$17.82
- CADLCandel Therapeutics Inc. Common Stock$8.19▼ 8.08%Market cap $775.20MP/E —$4.35$14
- RGNXREGENXBIO Inc. Common Stock$6.93▼ 3.28%Market cap $583.15MP/E —$5.46$16.19
- TECXTectonic Therapeutic Inc. Common Stock$20.65▼ 3.05%Market cap $570.23MP/E —$14.6$39.53
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALLO Allogene Therapeutics Inc. Common Stock | $679.95M | — | $1.31 | ▼ 2.24% | $1.04$4.46 |
| AGMB AgomAb Therapeutics NV American Depositary Shares | $664.85M | — | $8.28 | ▼ 0.60% | $7.97$17.82 |
| CADL Candel Therapeutics Inc. Common Stock | $775.20M | — | $8.19 | ▼ 8.08% | $4.35$14 |
| RGNX REGENXBIO Inc. Common Stock | $583.15M | — | $6.93 | ▼ 3.28% | $5.46$16.19 |
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $20.65 | ▼ 3.05% | $14.6$39.53 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline PivotYahoo · 9/15/2026
- Cellectis Pivots to Gene Editing in Major OverhaulBenzinga · 9/14/2026
- Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?Yahoo · 9/11/2026
Insider Activity
Insider Actions →- Earl Martin Douglas · August 21, 2026 · Sale29.7K @ $2.12
- Zachary Roberts · July 1, 2026 · Grant476.2K
- Zachary Roberts · July 1, 2026 · Grant134.5K
- Joshua A. Kazam · June 18, 2026 · Option Exercise47.7K
- Vicki L. Sato · June 18, 2026 · Grant95.4K
- Barrett Elizabeth A. · June 18, 2026 · Grant95.4K
- Deborah M. Messemer · June 18, 2026 · Grant95.4K
- Stephen Mayo · June 18, 2026 · Grant144.4K
- WITTE OWEN N. · June 18, 2026 · Grant95.4K
- Humer Franz B · June 18, 2026 · Grant95.4K
- Joshua A. Kazam · June 18, 2026 · Grant95.4K
- Annie Yoshiyama · April 21, 2026 · Sale9.6K @ $2.31
Institutional Ownership
March 31, 2026
- Total shares held
- 180.17M
- Total value held
- $419.65M
- Institutional holders
- 203
- Unknown22.03M
- Unknown19.09M
- Unknown18.72M
- Unknown8.66M
- Unknown8.38M
- Unknown6.92M
- Unknown6.89M
- Unknown5.38M
- Unknown5.38M
- Unknown4.12M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns
Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.